Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
65 studies found for:    NIAID | Open Studies | Exclude Unknown | anthrax OR botulism OR plague OR pox OR tularemia OR Viral hemorrhagic fever OR Dengue OR Ebola OR Marburg OR aureus OR flu OR tuberculosis OR hantavirus
Show Display Options
Rank Status Study
1 Recruiting Evaluating the Safety of and Immune Response to a Dengue Vaccine (TV003) in Healthy Adults, Adolescents, and Children in Thailand
Condition: Dengue
Interventions: Biological: TV003;   Biological: Placebo for TV003
2 Recruiting Training Protocol on the Natural History of Tuberculosis
Condition: Tuberculosis
3 Recruiting Ebola Virus Disease Survivors: Clinical and Immunologic Follow-up
Condition: Ebola Virus Disease
4 Recruiting GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen
Condition: Persistent Ebola Virus
Interventions: Drug: GS-5734;   Other: Placebo Comparator
5 Recruiting Effect of Filarial Infection on Immune Responses in Latent Tuberculosis
Conditions: Tuberculosis;   Filariasis
6 Recruiting Influenza A H3N2 Human Challenge Study in Healthy Adult Volunteers
Condition: Determine Minimally to Moderately Infective Dose (MMID) of Influenza A H3N2
Intervention: Other: Live recombinantly derived A/Bethesda/MM1/H3N2 virus
7 Not yet recruiting NexGen EBA Radiologic and Immunologic Biomarkers of Sterilizing Drug Activity in Tuberculosis
Condition: Tuberculosis
Interventions: Drug: Moxifloxacin;   Drug: Pyrazindamide;   Drug: Rifampicin;   Drug: Isonizaid
8 Not yet recruiting Using Biomarkers to Predict TB Treatment Duration
Condition: Tuberculosis
Interventions: Procedure: blood draw;   Radiation: PET/CT;   Procedure: induced sputum
9 Recruiting Sputum Pharmacokinetics of TB Drugs and Bacterial Drug Resistance
Condition: Tuberculosis
10 Recruiting Natural History of Anthrax: a Study of Primary Infected, Recovered, and Exposed Individuals (SPoRE); and Evaluation of AVA-Vaccinated Recipients
Condition: Anthrax
11 Recruiting Immune Responses to Mycobacterium Tuberculosis (Mtb) in People With Latent Tuberculosis Infection With or Without Concomitant Helminth Infection
Condition: Latent Tuberculosis Infection
12 Recruiting Human Immunity Against Staphylococcus Aureus Skin Infection
Condition: Staphylococcus Aureus Skin Infection
Intervention: Other: Killed Bacteria
13 Recruiting Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza
Conditions: Influenza A;   Influenza B
Interventions: Biological: Intravenous hyperimmune immunoglobulin (IVIG);   Biological: Placebo for IVIG
14 Recruiting The Evaluation of Potential Zika, Chikungunya, and Dengue Infections in Mexico
Conditions: Zika Virus Disease (Disorder);   Dengue;   Chikungunya
15 Recruiting Influenza in People With Normal and Weakened Immune Systems
Condition: Influenza
16 Recruiting Zoonotic Influenza Infections of Swine Origin at Ohio Agricultural Fairs
Condition: Influenza
17 Recruiting Screening Volunteers for Influenza Challenge Studies
Condition: Influenza, Human
18 Recruiting Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults
Condition: Influenza, Human
Interventions: Drug: Oseltamivir;   Drug: Oseltamivir Placebo
19 Recruiting Study in Healthy Volunteers to Evaluate the Efficacy and Safety of CR6261 in an H1N1 Influenza Healthy Human Challenge Model
Condition: H1N1 Influenza Healthy Volunteers
Interventions: Biological: CR6261;   Biological: Placebo
20 Recruiting Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A
Condition: Influenza A Virus Infection
Interventions: Biological: High-titer anti-influenza plasma;   Biological: Low-titer (control) anti-influenza plasma

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years